Randomized 5-treatment crossover study to assess the effects of external heat on serum fentanyl concentrations during treatment with transdermal fentanyl systems

Journal of Clinical Pharmacology

Volumn 52, Issue 8, 2012, Pages 1174-1185

  Moore, Kenneth T ^a   Sathyan, Gayatri ^b   Richarz, Ute ^c   Natarajan, Jaya ^a   Vandenbossche, Joris ^d  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Adamas India Pharmaceuticals Private Limited   (India)

^c JOHNSON AND JOHNSON   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

external heat; serum concentration; Transdermal fentanyl

Indexed keywords

FENTANYL; NALTREXONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HEATING; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; FEMALE; FENTANYL; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; YOUNG ADULT;

EID: 84864416378     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011411710     Document Type: Article

References (27)

1. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids, focus on transdermal fentanyl. Clin Pharmacokinet. 2000 ; 38: 59-89 (Pubitemid 30055094)
2. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997 ; 53: 109-138 (Pubitemid 27042235)
3. Kroll W, List WF. Pain treatment in the ICU: intravenous, regional or both?. Eur J Anesthesiol Suppl. 1997 ; 15: 49-52
4. Andrews CJH, Prys-Roberts C. Fentanyl: a review. Clin Anesthesiol. 1983 ; 1: 97-122
5. Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology. 1999 ; 90: 576-599 (Pubitemid 29071528)
6. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983 ; 8: 422-446 (Pubitemid 13009122)
7. McClain DA, Hug CC. Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980 ; 28: 106-114 (Pubitemid 10090693)
8. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001 ; 61: 2289-2307 (Pubitemid 34074808)
9. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989 ; 70: 928-934 (Pubitemid 19148495)
10. Lilleng PK, Mehlum LI, Bachs L, Morild I. Deaths after intravenous misuse of transdermal fentanyl. J Forensic Sci. 2004 ; 49: 1364-1366 (Pubitemid 39453200)
11. Kuhlman JJ, McCaulley R, Valouch TJ, Behonick GS. Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J Anal Toxicol. 2003 ; 27: 499-504 (Pubitemid 37185862)
12. Sathyan G, Guo C, Sivakumar K, Gidwani S, Gupta S. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin. 2005 ; 21: 1961-1968 (Pubitemid 41803107)
13. Moore KT, Adams HD, Natarajan J, Ariyawansa J, Richards HM. Bioequivalence and safety of a novel fentanyl transdermal matrix system compared with a transdermal reservoir system. J Opioid Manag. 2011 ; 7: 99-107
14. Ashburn MA, Ogden LL, Zhang J, Love G, Basta SV. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain. 2003 ; 4: 291-297 (Pubitemid 37013019)
15. Shomaker TS, Zhang J, Ashburn MA. Assessing the impact of heat on the systemic delivery of fentanyl through the transdermal fentanyl delivery system. Pain Med. 2000 ; 1: 225-230
16. Carter KA. Heat-associated increase in transdermal fentanyl absorption. Am J Health Syst Pharm. 2003 ; 60: 191-192 (Pubitemid 36427053)
17. Rose PG, Macfee MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg. 1993 ; 77: 390-391 (Pubitemid 23221443)
18. Frolich M, Giannotti A, Modell JH. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg. 2001 ; 93: 647-648 (Pubitemid 32783289)
19. FDA public health advisory: important information for the safe use of fentanyl transdermal system (patch) 12/21/2007. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM051257. Accessed March 10, 2011.
20. Gidwani S, Sathyan G, Sun T, Gupta SK Pain Practice. Devor M Erdine S Ruiz-Lopez R, ed. Cambridge, MA: Blackwell ; 2004: 288-289.
21. Adams M, Pieniaszek HJ, Gammaitoni AR, Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol. 2005 ; 45: 337-345 (Pubitemid 40490430)
22. Metropolitan height and weight tables. Stat Bull Metrop Insur Co. 1983 ; 64: 2-9
23. Duragesic medication guide. Ortho-McNeil-JanssenPharmaceuticals Inc. 2009. Available at: http://www.duragesic.com/sites/default/files/pdf/duragesic- medguide-0.pdf. Accessed October 12, 2010.
24. Chow S, Liu J Design and Analysis of Bioavailability and Bioequivalence Studies. Chow S Liu J, ed. New York, NY: Marcel Dekker ; 1992: 70-125.
25. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 ; 15: 657-680
26. Phipps B, Cormier M, Gale B, et al Encyclopedia of Biomaterials and Biomedical Engineering. Bowlin GL Wnek G, ed. New York, NY: Marcel Dekker ; 2004: 1677-1689.
27. Prodduturi S, Sadrieh N, Wokovich AM, Doub WH, Westenberger BJ, Buhse L. Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin. J Pharm Sci. 2010 ; 99: 2357-2366